BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 10417342)

  • 21. Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
    Zhang W; Ling D; Tan J; Zhang J; Li L
    Oncol Rep; 2013 Feb; 29(2):637-45. PubMed ID: 23174953
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urokinase-type plasminogen activator induces proliferation in breast cancer cells.
    Gandhari M; Arens N; Majety M; Dorn-Beineke A; Hildenbrand R
    Int J Oncol; 2006 Jun; 28(6):1463-70. PubMed ID: 16685447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
    Krüger A; Soeltl R; Lutz V; Wilhelm OG; Magdolen V; Rojo EE; Hantzopoulos PA; Graeff H; Gänsbacher B; Schmitt M
    Cancer Gene Ther; 2000 Feb; 7(2):292-9. PubMed ID: 10770639
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Domain structure and interactions of recombinant urokinase-type plasminogen activator.
    Novokhatny V; Medved L; Mazar A; Marcotte P; Henkin J; Ingham K
    J Biol Chem; 1992 Feb; 267(6):3878-85. PubMed ID: 1310986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of bFGF on invasion of ovarian cancer cells through the regulation of Ets-1 and urokinase-type plasminogen activator.
    Li T; Jiang S
    Pharm Biol; 2010 Feb; 48(2):161-5. PubMed ID: 20645833
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator.
    Mohanam S; Chandrasekar N; Yanamandra N; Khawar S; Mirza F; Dinh DH; Olivero WC; Rao JS
    Oncogene; 2002 Nov; 21(51):7824-30. PubMed ID: 12420219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect.
    Resnati M; Guttinger M; Valcamonica S; Sidenius N; Blasi F; Fazioli F
    EMBO J; 1996 Apr; 15(7):1572-82. PubMed ID: 8612581
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urinary-type plasminogen activator (uPA) and its receptor (uPAR) in squamous cell carcinoma of the oral cavity.
    Shi Z; Stack MS
    Biochem J; 2007 Oct; 407(2):153-9. PubMed ID: 17880283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
    Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
    BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
    McGowen R; Biliran H; Sager R; Sheng S
    Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
    Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
    Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo.
    Pass J; Jögi A; Lund IK; Rønø B; Rasch MG; Gårdsvoll H; Lund LR; Ploug M; Rømer J; Danø K; Høyer-Hansen G
    Thromb Haemost; 2007 Jun; 97(6):1013-22. PubMed ID: 17549305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
    Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
    Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic downregulation of pregnancy-associated plasma protein-A (PAPP-A) by bikunin reduces IGF-I-dependent Akt and ERK1/2 activation and subsequently reduces ovarian cancer cell growth, invasion and metastasis.
    Tanaka Y; Kobayashi H; Suzuki M; Hirashima Y; Kanayama N; Terao T
    Int J Cancer; 2004 Apr; 109(3):336-47. PubMed ID: 14961570
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC-3).
    Angelloz-Nicoud P; Binoux M
    Endocrinology; 1995 Dec; 136(12):5485-92. PubMed ID: 7588299
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium.
    Young TN; Rodriguez GC; Moser TL; Bast RC; Pizzo SV; Stack MS
    Am J Obstet Gynecol; 1994 May; 170(5 Pt 1):1285-96. PubMed ID: 8178854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasminogen fragmentation and increased production of extracellular matrix-degrading proteinases are associated with serous epithelial ovarian cancer progression.
    Murthi P; Barker G; Nowell CJ; Rice GE; Baker MS; Kalionis B; Quinn MA
    Gynecol Oncol; 2004 Jan; 92(1):80-8. PubMed ID: 14751142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ovarian cancer cells stimulate uPA gene expression in fibroblastic stromal cells via multiple paracrine and autocrine mechanisms.
    Noskova V; Ahmadi S; Åsander E; Casslén B
    Gynecol Oncol; 2009 Oct; 115(1):121-126. PubMed ID: 19631971
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostatic kallikrein hK2, but not prostate-specific antigen (hK3), activates single-chain urokinase-type plasminogen activator.
    Frenette G; Tremblay RR; Lazure C; Dube JY
    Int J Cancer; 1997 May; 71(5):897-9. PubMed ID: 9180162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.